-
Mashup Score: 13
Proposed acquisition adds Nimble’s lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 8AbbVie Completes Acquisition of Aliada Therapeutics - 15 day(s) ago
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer’s disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: @aliadatx is now part of AbbVie. This #acquisition expands our neuroscience pipeline with an investigational therapy in #Alzheimers disease and a novel blood-brain barrier-crossing technology. Read more: https://t.co/A2LWpGAHaL $ABBV https://t.co/2GAIbZ8BQK
-
-
Mashup Score: 8
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced new…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: We are presenting new data at #ASH24 evaluating our investigational treatment for diffuse large B-cell #lymphoma patients, in collaboration with @Genmab. Explore: https://t.co/72DgcZdeUj https://t.co/kwF7Rs4iow
-
-
Mashup Score: 4AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease - 17 day(s) ago
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
JUST IN: Today, we announced results from a Phase 3 trial of our investigational #ParkinsonsDisease treatment. Learn more: https://t.co/JrCHyEMXbe https://t.co/fVO4gSBU6A
-
-
Mashup Score: 9
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 7, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced updated…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
JUST IN: We’re sharing new data at #ASH24 evaluating our investigational treatment for patients with relapsed or refractory follicular #lymphoma, in collaboration with @Genmab. Read more: https://t.co/FE24Cp2XrQ https://t.co/zKaj1nbrcx
-
-
Mashup Score: 13AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer - 1 month(s) ago
ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer ELAHERE…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: The @EMA_News has approved our treatment for platinum-resistant #OvarianCancer. Read more: https://t.co/8uq4H8nBfF
-
-
Mashup Score: 10AbbVie Reports Third-Quarter 2024 Financial Results - 2 month(s) ago
Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
#ICYMI: This morning we released our Q3 2024 #FinancialResults. Read more about our performance: https://t.co/pUyBgC3qu3 $ABBV #earnings
-
-
Mashup Score: 12AbbVie Reports Third-Quarter 2024 Financial Results - 2 month(s) ago
Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00, an Increase of 1.7 Percent; These Results Include an Unfavorable Impact of…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: Our Q3 2024 #FinancialResults are in. Learn more: https://t.co/HLl5si3xX7 $ABBV #earnings https://t.co/EIBGayWNsG
-
-
Mashup Score: 13AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline - 2 month(s) ago
Aliada’s lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer’s disease Acquisition also allows AbbVie to utilize…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: We announced the acquisition of @aliadatx in a pivotal move to strengthen our #neuroscience portfolio, with the goal of accelerating the development of novel therapies for neurological disorders like Alzheimer’s disease. Learn more: https://t.co/02kU0nmHxE https://t.co/VgCyNp4FYx
-
-
Mashup Score: 19U.S. FDA Approves VYALEV™ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease - 2 month(s) ago
VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson’s disease Adults treated with…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet-
NEWS: The @US_FDA has approved our treatment in advanced #ParkinsonsDisease. Read more: https://t.co/VW1QdjFKuw
-
JUST IN: We’ve signed a definitive agreement to acquire Nimble Therapeutics to further strengthen our #immunology pipeline, with a goal of developing novel medicines for people living with #autoimmune diseases. Learn more: https://t.co/oeT8ji285B https://t.co/xk6K0E5tWW